pharma&
pharma& is a Vienna company that buys and markets established medicines, including the PARP inhibitor rucaparib (Rubraca), which it acquired from Clovis Oncology's bankruptcy in 2023.
Overview
pharma& (pharmaand GmbH), based in Vienna, acquires and commercialises marketed medicines rather than developing new molecules. In oncology it bought rucaparib (Rubraca), the PARP inhibitor approved for BRCA-mutated ovarian and prostate cancer, from Clovis Oncology in 2023 after Clovis filed for bankruptcy, and it now holds the US and EU authorisations and runs the remaining trials and post-marketing commitments. It appears on OnCo as an FDA oncology applicant and a phase 3 trial sponsor on ClinicalTrials.gov.
Scorecard
All companies- approved products +6
- targets +4
- modalities +2
- regions +4
- registry trials +14
Similar pages
not linked directly; found by shared links- CompanyShenzhen Ionova Life Sciences
Shares Ovarian cancer, Prostate cancer and the tag ctgov-sponsor.
- CompanyBavarian Nordic
Shares Prostate cancer and the tag ctgov-sponsor.
- CompanyEvopoint Biosciences
Shares Ovarian cancer, Prostate cancer and the tag ctgov-sponsor.
- CompanyFutureChem
Shares Prostate cancer and the tag ctgov-sponsor.
- CompanyHinova Pharmaceuticals
Shares Prostate cancer and the tag ctgov-sponsor.
- CompanySpectraCure
Shares Prostate cancer and the tag ctgov-sponsor.
- CompanyImunon
Shares Ovarian cancer and the tag ctgov-sponsor.
- CompanyNuvation Bio
Shares Ovarian cancer, Prostate cancer and the tag ctgov-sponsor.